AVITA Medical, Inc. (AVHHL)
OTCMKTS · Delayed Price · Currency is USD
1.115
-0.135 (-10.80%)
At close: Oct 8, 2025
AVITA Medical Revenue
AVITA Medical had revenue of $18.42M in the quarter ending June 30, 2025, with 21.21% growth. This brings the company's revenue in the last twelve months to $74.88M, up 38.32% year-over-year. In the year 2024, AVITA Medical had annual revenue of $64.25M with 28.14% growth.
Revenue (ttm)
74.88M
Revenue Growth
+38.32%
P/S Ratio
1.58
Revenue / Employee
288.02K
Employees
260
Market Cap
118.01M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 64.25M | 14.11M | 28.14% |
| Dec 31, 2023 | 50.14M | 15.72M | 45.68% |
| Dec 31, 2022 | 34.42M | 1.40M | 4.23% |
| Dec 31, 2021 | 33.03M | 3.79M | 12.98% |
| Jun 30, 2021 | 29.23M | 14.97M | 104.95% |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| American Oncology Network | 1.76B |
| Veradigm | 588.02M |
| Jushi Holdings | 256.36M |
| Glass House Brands | 221.55M |
| Elite Pharmaceuticals | 105.45M |
| Silence Therapeutics | 27.17M |
| Nuo Therapeutics | 1.95M |
| Northwest Biotherapeutics | 1.09M |
AVITA Medical News
- 14 days ago - INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AVITA Medical, Inc. - RCEL - PRNewsWire
- 15 days ago - AVITA Medical (RCEL) Shares Plummet as Interim CEO Appointed - GuruFocus
- 15 days ago - RCEL: Lake Street Downgrades AVITA Medical to Hold, PT Slashed by 50% | RCEL Stock News - GuruFocus
- 15 days ago - Avita Medical (RCEL) Forecasts $17 Million in Q3 Revenue - GuruFocus
- 15 days ago - AVITA Medical (RCEL) Appoints Interim CEO and Updates Revenue Guidance - GuruFocus
- 15 days ago - AVITA Medical Appoints Cary Vance As Interim CEO - Nasdaq
- 16 days ago - AVITA Medical Announces CEO Transition - GlobeNewsWire
- 16 days ago - AVITA MEDICAL INVESTIGATION: Bragar Eagel & Squire, P.C. Reminds AVITA Medical Investors to Contact the Firm Regarding the Ongoing Investigation on Behalf of Stockholders - GlobeNewsWire